2025-525113-22-00RecruitingPhase 1
A First-in-Human, Open-label, Phase 1 Study to Evaluate Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of NBIM-1008 in Patients with Rheumatoid Arthritis
Source: EU CTIS (euclinicaltrials.eu) · Last updated 10 Aug 2026
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (estimated)
- First submitted
- 17 Mar 2026
- Start date
- 10 Jun 2026
- Lead sponsor
- Neurocrine Biosciences Inc.
- Diseases
- Rheumatoid arthritis
- EU CT number
- 2025-525113-22-00
What you commit to
- Study type: Interventional · Phase 1
- Planned participants: 15
- 3 sites in 2 countries
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of EU CTIS (euclinicaltrials.eu). It describes the study design.
AI-kivonat: who the study is looking for
Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with rheumatoid arthritis to test the safety and early effect of a new treatment, NBIM-1008, in humans for the first time.
- Age
- 18 to 64 years
- Sex
- All sexes can join.
Read by machine on 9 Nov 2026.
Sites (3)
Sites in registry order. Save your city in your profile to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Biokinetica S.A. | Jozefow | Poland | Recruiting |
| Arensia Clinics S.R.L. | Bucharest | Romania | Recruiting |
| Spitalul Clinic Judetean De Urgenta Cluj | Cluj-Napoca | Romania | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.